Skip to main content
. 2022 Jun 24;12(6):96. doi: 10.1038/s41408-022-00688-4

Fig. 5. Data for survival and use of allo-HSCT after CAR-T cell treatment for patients with R/R B-ALL enrolled in the clinical study (n = 21).

Fig. 5

All 18 efficacy-evaluable patients (100%) were followed for at least 3 months; 15 of these patients (83.3%) maintained disease-free survival (DFS) at the 3-month assessment, and 14 patients (77.8%) remained MRD negative at 3 months. The longest time of disease-free survival was 29 months.